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Mitochondria-targeted antioxidantThe purpose of our study was to assess mitochondrial biogenesis and distribution in murine primary neurons.
Using 5-bromo-2-deoxyuridine (BrdU) incorporation and primary neurons, we studied the mitochondrial
biogenesis and mitochondrial distribution in hippocampal neurons from amyloid beta precursor protein
(AβPP) transgenic mice and wild-type (WT) neurons treated with oxidative stressors, rotenone and H2O2. We
found that after 20 h of labeling, BrdU incorporation was speciﬁc to porin-positive mitochondria. The
proportion of mitochondrial area labeled with BrdU was 40.3±6.3% at 20 h. The number of mitochondria
with newly synthesized DNA was higher in AβPP neuronal cell bodies than in the cell bodies of WT neurons
(AβPP, 45.23±2.67 BrdU-positive/cell body; WT, 32.92±2.49 BrdU-positive/cell body; p=0.005). In
neurites, the number of BrdU-positive mitochondria decreased in AβPP cultures compared to WT neurons
(AβPP, 0.105±0.008 BrdU-positive/μm neurite; WT, 0.220±0.036 BrdU-positive/μm neurite; p=0.010).
Further, BrdU in the cell body increased when neurons were treated with low doses of H2O2 (49.6±2.7 BrdU-
positive/cell body, p=0.0002 compared to untreated cells), while the neurites showed decreased BrdU
staining (0.122±0.010 BrdU-positive/μm neurite, p=0.005 compared to the untreated). BrdU labeling was
increased in the cell body under rotenone treatment. Additionally, under rotenone treatment, the content of
BrdU labeling decreased in neurites. These ﬁndings suggest that Aβ and mitochondrial toxins enhance
mitochondrial fragmentation in the cell body, and may cause impaired axonal transport of mitochondria
leading to synaptic degeneration.; AD, Alzheimer's disease; ATP,
ine; Drp1, dynamin related
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Increasing evidence suggests that mitochondrial abnormalities are
involved in aging and in age-related neurodegenerative diseases, such
as Alzheimer's (AD), Huntington's (HD), Parkinson's (PD), and amyo-
trophic lateral sclerosis (ALS). Age-dependent, mitochondrially gener-
ated reactive oxygen species (ROS) have been identiﬁed as important
factors thatmay be responsible for disease progression and cell death in
these diseases [1–5]. Treatingmitochondria, particularly early on in the
disease process or even presymptomatic, is an important option to treat
these diseases.
A role for mitochondrial structural changes in mitochondrial
dysfunction is emerging from studies of postmortem brain slices frompatients with neurodegenerative diseases and of transgenic animal
models of these diseases [6–21]. The shape, structure, and distribution
of mitochondria are maintained by two important, opposite forces:
mitochondrial ﬁssion and mitochondrial fusion [22–24]. Fission is
controlled and regulated by the dynamin-related protein (Drp1) and
mitochondrial ﬁssion 1 (Fis1). The increase in mitochondrial free
radicals activates Fis1, which is critical for mitochondrial ﬁssion. In
contrast, mitochondrial fusion is controlled by 3 GTPase proteins: 2
outer-membrane localized proteins Mfn1 and Mfn2, and an inner-
membrane localized protein Opa1 [3,24,25].
In neurons from AD patients, mitochondrially generated free
radicals activated Fis1 and promoted an increase in mitochondrial
fragmentation, in turn producing defective mitochondria that ulti-
mately damaged neurons [26,27]. Mitochondrial fusion protected
cells from the toxic effects of Aβ by allowing functional complemen-
tation of mtDNA, proteins and metabolites.
The imbalance between ﬁssion and fusion in the mitochondria
appears to lead to functional changes, such as increased ROS
production and increased lipid peroxidation; and decreased respira-
tion, decreased ATP production, and decreased membrane potential.
This dysfunction and abnormality in mitochondrial dynamics occur
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subsequent high oxidative phosphorylation in these neurons [27,28].
Early detection of abnormal mitochondrial dynamics and mitochon-
drial dysfunction may allow us to intervene in disease processes in
order to affect disease progression and to limit disease effects.
One such abnormal mitochondrial dynamics is increased mito-
chondrial fragmentation and decreased mitochondrial fusion. Mito-
chondrial fragmentation is the breakup of a single mitochondrion
when the cell is exposed to toxins and/or when the cell expresses
mutant protein(s). Mitochondrial fragmentation is different from
mitochondrial division, which is the natural division of one mito-
chondrion into two. In both processes, synthesis of mitochondrial
DNA (mtDNA) occurs. Mitochondrial synthesis, turnover, and recy-
cling occur mainly in the cell body because mitochondrial proteins are
encoded mostly by nuclear DNA and these nuclear encoded
mitochondrial proteins are essential for mitochondrial synthesis
[28,29]. However, this process limits mitochondrial biogenesis to
the cell body, and delivery of mitochondria to the axons and nerve
terminals is dependent on axonal transport.
The hypothesis of “mitochondrial synthesis in cell body” was
studied in the earlier work of Davis and Clayton [30]. Using healthy
PC12 cells and in situ localization of mtDNA, they found that mtDNA
replication mainly occurs in the cell body. However, other studies
revealed that mitochondrial proteins were synthesized in the axons
[31–33], indicating that mitochondrial replication may occur in the
axons as well. This possibility is supported by research in which
mitochondrial replications were reported outside the perinuclear
region in healthy, non-neuronal cells [34–37]. The issue of where
mitochondrial replication occurs becomes even more complicated
when it is studied in diseased neurons, such as in neurons that express
mutant proteins or that are exposed to toxins. Amiri and Hollenbeck
[38] also studied whether mtDNA synthesis can occur in the axons of
neurons. Using 11-day primary neurons from the dorsal root ganglia
of chickens, and the 5-bromo-2-deoxyuridine (BrdU) incorporation
method, they found newly synthesized mtDNA in axons, indicating
that mitochondrial division occurs in axons. More recently, Lentz and
colleagues [39] used a new sensitive technique to label newly
synthesized mtDNA in individual cells by incorporating thymidine
analogs such as 5-ethynyl-2′-deoxyuridine (EdU) into mtDNA with a
tyramide signal ampliﬁcation protocol. This technique is a valuable
tool for visualizing and measuring mtDNA biogenesis within individ-
ual neurons and, importantly, within speciﬁc neuronal compartments,
such as the somas, dendrites, axons and synapses [39]. BrdU
incorporation has also been used to detect cells with new DNA
synthesis in ﬂow cytometry analysis [40].
Using mouse hippocampal neurons that were treated with
amyloid beta (Aβ) peptide 25–35 (a toxic peptide that is involved
in AD progression and pathogenesis), we studied axonal transport of
mitochondria, including the motility of mitochondria traveling along
the axons, the length and size of these mitochondria, and the
mitochondrial index per neurite. We also studied synaptic alterations
resulting from the axonal transport of mitochondria in the hippo-
campal neurons [15]. Our results suggest that the Aβ25–35 peptide
impairs axonal transport of mitochondria in AD neurons. Further, the
average speed of themotile mitochondria was decreased in the Aβ25–
35-treated neurons relative to PBS-treated control neurons. Further,
synaptic immunoreactivity was also signiﬁcantly less in the Aβ25–35-
treated neurons relative to the PBS-treated neurons, indicating that
Aβ25–35 affects synaptic viability [15]. It is still unclear whether, in
neurons that express Aβ, mtDNA is synthesized in axons and neurites,
or in the cell body and is then transported to axons/neurites and
terminals through natural axonal transport mechanisms.
In this study, 1) we evaluated the distribution of BrdU labeled
mtDNA in hippocampal neurons from AβPP mice. 2) Further, we also
studied BrdU labeled mitochondria from neurons of wild-type mice in
response to both acute and chronic toxicity from oxidative stressors,H2O2, and rotenone. 3) Additionally we studied the response of BrdU
labeled mitochondria to known neuroprotective molecules such as
SS31 and resveratrol.
2. Materials and methods
2.1. Mice and primary neuronal cultures
The amyloid beta precursor protein (AβPP) transgenic mice
(Tg2576 line) and the non-transgenic wild-type (WT) littermates
are housed at the Oregon National Primate Research Center animal
facility. The AβPP mice were generated with the mutant human APP
gene 695 amino acid isoform and with a double mutation (Lys670Asn
and Met671Leu) [41]. The Tg2576 mice were gifted by Karen Ashe,
PhD, University of Minnesota. All procedures were performed during
the light cycle and were approved by the Institutional Animal Care
and Use Committee (IACUC) at Oregon Health & Science University.
Primary neurons were prepared as previously described [7,15].
Brieﬂy, AβPP and wild-type pups (P0–1) were decapitated, and brains
were removed into room temperature HABG (Hibernate A medium;
Brain Bits, Springﬁeld, IL) supplemented with B-27 (Invitrogen,
Carlsbad, CA) and 0.5 mM GlutaMAX (Invitrogen). The hippocampus
was dissected and reserved for culture, and the cerebellum was used
for genotyping. Tissue was minced into pieces and then transferred
into a solution of 2 mg/ml papain (Worthington Biochemical Corp.,
Lakewood, NJ) that was dissolved in Hibernate A without Ca2+ (Brain
Bits) and supplemented with 0.5 mM GlutaMAX. The tissue was
digested for 30 min at 30 °C in a shakingwater bath and then removed
into 2 ml HABG. Digested tissue was triturated 10 times with a ﬁre-
polished, siliconized, 9-in. glass pipette. Non-dissociated tissue was
allowed to settle for 2 min, and then the supernatant was removed
into a fresh tube. An additional 2 ml of HABG was added, and the
process was repeated until 6 ml of dissociated cells was collected.
Cells were centrifuged at 200 g for 2 min and then washed with
2 ml HABG. The pellets were resuspended in Neurobasal (Invitrogen)
supplemented with B-27 and 0.5 mM GlutaMAX. Live cells were
counted using the trypan blue exclusion method and plated at
500 cells/mm2 on poly-D-lysine-coated plates or coverslips. Cells were
moved into a 37 °C, 5% CO2 incubator and allowed to adhere for 1 h.
Medium was then changed to Neurobasal, supplemented with B-27
minus antioxidants and 0.5 mM GlutaMAX. One-half of the growth
medium was changed every 3 days.
2.2. Cell treatments
Wild-type cells were treated with SS31 (1 nM, Anaspec, Freemont,
CA) or resveratrol (10 μM, Sigma-Aldrich) for 48 h. At 20 h prior to
harvest, cells were treated with 15 μM 5-bromo-2′-deoxyuridine
(BrdU, Sigma-Aldrich, St. Louis, MO). Similarly, wild-type neurons
were treated with H2O2 or rotenone for 24 h with 20 h BrdU labeling
chronologically. Cells were used at 10 DIV.
2.3. BrdU labeling
MtDNA synthesis was measured by BrdU incorporation [39]. Cell
cultures grownon13 mmround coverslipswere incubatedwith aﬁnal
concentration of 15 μM BrdU for either 4 or 20 h, after which time the
cells were ﬁxed with 4% paraformaldehyde for 10 min at room
temperature. Coverslips were washed with PBS and then incubated
for 10 minwith 0.1% TritonX-100 to permeabilize themembranes. The
BrdU epitope was exposed by incubating the cells in 2 N hydrochloric
acid for 1 h at 37 °C. Then endogenous peroxidase activity was
quenched with 0.3% hydrogen peroxide in PBS for 30 min at room
temperature. After beingwashedwith PBS, cultureswere blockedwith
1% bovine serum albumin and 2% normal goat serum in PBS (blocking
solution). A primary antibody (anti-BrdU, mouse monoclonal, BD
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solution, and incubated at room temperature for 1 h. Cells were
washed three times with PBS and then incubated with secondary
antibody (anti-mouse-HRP, goat polyclonal, KPL, Gaithersburg,MD) at
a 1:200 dilution for 1 h at room temperature in a blocking solution.
BrdU was then detected with Tyramide-488 signal ampliﬁcation
(Invitrogen). Tyramide-488 was diluted 1:100 into assay buffer with
0.15% hydrogen peroxide, and the cells were incubated with the
solution for 5 min. The cells were then washed with PBS and either
mounted onto slides for image acquisition or co-labeled with
mitochondrial or neuronal markers.
Co-labeled cells were then incubated with either a primary
antibody for a voltage-dependent anion channel (VDAC/porin) (rabbit
polyclonal, Abcam, San Francisco, CA) at 1:200 in blocking solution or
MAP-2 (rabbit polyclonal; Millipore, Billerica, MA) at 1:1000 in
blocking solution at 4 °C overnight. After being washed, coverslips
were incubated with secondary antibody (goat anti-rabbit-Alexa 568,
Invitrogen) and diluted 1:400 in a blocking solution for 2 h at room
temperature. Coverslips were washed with PBS and mounted onto
slides with the Prolong Gold mounting medium.
2.4. BrdU quantiﬁcation
Imageswere collected from at least three independent cultures per
group. To assess the percentage of mitochondria that took BrdU
labeling, we collected images of BrdU-stained and porin-co-labeled
neurons. Areas of staining were assessed using ImageJ software. The
area of BrdU staining was normalized to porin staining, and the
percentage of mitochondria with BrdU-labeled DNA was calculated.
To assess the subcellular localization of BrdU-labeled mitochondria,
the number of BrdU-stained mitochondria in neuronal cell bodies was
assessed and normalized to the number of cell bodies present, and the
number of BrdU-positive mitochondria was counted in neuronalFig. 1. BrdU staining is localized to mitochondria in primary neuronal cultures. Primary hipp
incorporation. Cells were then co-labeled with MAP-2 (neuronal marker) or porin (mitoch
showed robust BrdU labeling as puncta within the cell body and neurites. These BrdU puncta
the mtDNA. Enlargements (C— lower panels) show co-localization of BrdU is speciﬁc to porin
d, BrdU; e, porin; and f, merged.projections and was normalized to the total length of neuronal
projections. To assess the distribution of BrdU-labeled mitochondria,
neurites that were imaged for at least 50 μm from the soma were
evaluated. The distance from the soma was calculated for each BrdU-
labeled mitochondrion. Data were binned into 5-μm groups, and the
percentage of BrdU-positive mitochondria in each bin was assessed.
Cumulative probability was calculated as the percentage of BrdU-
positive mitochondria within 50 μm of the cell body that was found
less than a set distance from the cell body.
2.5. Data analysis and statistics
All quantitativedata are reported as average±S.E.M.Comparisonsof
multiple groups were made using ANOVA with Bonferroni post-test.
Whenonly twogroupswere compared, anunpairedStudent's t-testwas
performed. A pb0.05 was considered statistically signiﬁcant.
3. Results
3.1. BrdU-labeled mitochondria appear in neuronal cell bodies and in
neuritic processes
To test whether newly synthesized mtDNA is in neuronal cell
processes, we labeled wild-type primary neurons with BrdU for 20 h
and then stained them with neuron-speciﬁc protein, MAP-2 (Fig. 1).
We found that most of the neuronal projections contained BrdU-
labeled mitochondria. Further, we observed that the number of
mitochondria labeled with BrdU decreased as their distance increased
from the cell body. While we did not assess the site at which mtDNA
synthesis occurs, our observation suggests that mtDNA synthesis
occurs preferentially in close proximity to the nucleus. After somatic
DNA synthesis, the mitochondria would be expected to undergo
anterograde transport and populate neurites.ocampal neurons were incubated with BrdU for 20 h and then stained to visualize BrdU
ondrial marker). Primary neurons as identiﬁed by MAP-2 staining (A — upper panels)
co-localized with porin (B—middle panels), indicating that BrdUwas incorporated into
-stained organelles (arrowheads). Enlargements represent a, BrdU; b, porin; c, merged;
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To verify that BrdU labeling was indeed speciﬁc to mtDNA, we
labeled primary neurons with BrdU and then immunostained the
same cells for the mitochondrial outer membrane localized protein,
porin. After 20 h of incubation, BrdU incorporation was speciﬁc to the
porin-positive mitochondria (Fig. 1). The proportion of mitochondrial
area that was labeled with BrdU was about 40.3±6.3% at 20 h
indicating that newly synthesized DNA is present in large numbers of
mitochondria within neurons.3.3. Mitochondria with new DNA synthesis exist largely in cell bodies of
AβPP neurons
To examine the effects of chronic Aβ exposure on mtDNA synthesis,
we monitored mtDNA biosynthesis by counting BrdU-labeled mito-
chondria in the cell bodies and neurites of primary neurons, fromwild-
type and AβPP mice at 10 DIV (Fig. 2A). After 20 h of BrdU incubation,
the number ofmitochondriawith newly synthesizedDNAwashigher in
the cell bodies of the AβPP neurons than of the wild-type neurons
(Fig. 2B, AβPP: 45.23±2.67 BrdU-positive/cell body; WT: 32.92±2.49
BrdU-positive/cell body; p=0.005). In neurites, the number of BrdU-
positive mitochondria was less in the AβPP cultures compared to the
wild-type cultures (Fig. 2B, AβPP: 0.105±0.008 BrdU-positive/μm
neurite; WT: 0.220±0.036 BrdU-positive/μm neurite; p=0.010). We
also assessed the distribution of BrdU-labeled mitochondria in neurites
up to 50 μmfromthe cell body. AβPPneuronshad ahigher percentage of
neuritic mitochondria found closer to the cell body, suggesting that the
decrease in mitochondria in the AβPP neurites results from deﬁciencies
in mitochondrial transport within these cells (Fig. 2C). AβPP cells had a
statistically signiﬁcant increase in mitochondria within 15 μm, 20 μm,
and 25 μmof the cell body, compared to wild-type cells (Fig. 2D). In the
wild-type cells, the proportion of BrdU-positive mitochondria within
25 μm of the cell body was 68.0±4.3%, while in the AβPP cells, theFig. 2. AβPP primary hippocampal neurons show increased BrdU staining in the cell body and
mice were incubated with BrdU for 20 h at 10 DIV and then stained for analysis. Represen
mitochondria in the cell body and neurites is shown (B). Quantiﬁcation of BrdU puncta dist
proportion of BrdU-stained puncta in 5-μmbins is shown (C), while the proportion of BrdU p
of BrdU-labeled mitochondria were in close proximity to the cell body in the AβPP culturesproportion of the BrdU-labeled mitochondria within 25 μm of the cell
body was 81.5±3.8% (Fig. 2D) (p=0.043).
To testwhether the distribution of BrdU-labeledmitochondria could
be altered over a short time course of BrdU incorporation, cells were
incubated with BrdU for 4 h and then harvested for analysis. BrdU-
positive mitochondria were counted separately in neuronal cell bodies
and in neurites. In the AβPP cells, BrdU-positive mitochondria were
more densely localized in the cell body compared to the wild-type cells
(Fig. 3A). Conversely, BrdU-positive mitochondria were less densely
localized in the neurites of the AβPP cells compared to the wild-type
cells.Wild-type neurons exhibited 4.61±0.65 BrdU-positivemitochon-
dria per cell body and 0.087±0.010 BrdU-positivemitochondria per μm
of neurite length (Fig. 3B). In comparison, AβPPneurons had 8.42±1.13
BrdU-positivemitochondria per cell body (p=0.013 compared towild-
type) and 0.049±0.007 BrdU-positive mitochondria per μm neurite
length (p=0.005 compared to wild-type).3.4. Cells treated with mitochondrial toxins show increased soma
mitochondria in BrdU labeling
In wild-type cells treated with 25 μMH2O2 for 24 h (Fig. 4B), BrdU
labeling was greater in the cell body (Fig. 4I, 49.6±2.7 BrdU-positive/
cell body, p=0.0002) compared to the untreated cells in the neurites
(Fig. 4K, 0.122±0.010 BrdU-positive/μm neurite, p=0.005 compared
to untreated). In the cells treated with 100 μM H2O2, BrdU labeling of
both the cell body and the neuritic mitochondria was less than the
labeling in the untreated cells (Fig. 4I and K, 20.8±3.3 BrdU-positive/
cell body, p=0.009 compared to the untreated; 0.065±0.004 BrdU-
positive/μm neurite, p=0.0002 compared to the untreated).
BrdU labeling was also evaluated in wild-type cells treated with
rotenone at 12.5 nM and 50 nM for 24 h (Fig. 4C, F, I and K). BrdU
labeling in the cell body progressively increased as the quantity of
rotenone increased (12.5 nM rotenone, 37.4±5.9 BrdU-positive/cell
body, p=0.218 compared to the untreated; 50 nM rotenone, 43.0±3.8decreased BrdU staining in neurites. Primary neurons grown from AβPP and wild-type
tative images of AβPP and WT neurons are shown (A). Quantiﬁcation of BrdU-labeled
ribution in relation to the cell soma was performed and analyzed by two methods. The
uncta within a certain length of neuritic distance is also shown (D). A higher proportion
compared to the wild-type cultures.
Fig. 3. Primary neurons from AβPP mice showed altered BrdU distribution even after short-term BrdU incubation. Representative images of AβPP primary hippocampal neurons that
were incubated with BrdU for 4 h are shown (A). Quantiﬁcation of cell body and BrdU puncta in neurites is shown (B).
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labeling content progressively decreased in the neurites as the quantity
of rotenone increased (Fig. 4K, 12.5 nM rotenone, 0.133±0.018 BrdU-
positive/μm neurite, p=0.015 compared to the untreated; 50 nMFig. 4. Both oxidative toxins and neuroprotective molecules alter the distribution of BrdU-s
and resveratrol (G) for 48 h, or with H2O2 (B and E) and rotenone (F) for 24 hwere assayed fo
enlargements of the cell body and selected neurites are shown. SS31 treatment resulted in n
staining in the neurites (G, H and J). Images show that resveratrol treatment did not alter Brd
accumulation of BrdU puncta in the cell body and a reduction in the neuritic processes (B, I a
and neurites. Two doses of rotenone that did not cause overt toxicity in the culture resulted
BrdU staining, in neurites (C, F, I and K). Quantiﬁcation of images frommultiple cultures is sho
to the vehicle-treated group.rotenone, 0.086±0.009 BrdU-positive/μm neurite, p=0.0005 com-
pared to the untreated). Overall, under mildly toxic conditions, BrdU
labeling decreased in neurites with increasingly larger cell bodies.
Moreover, BrdU-labeled mitochondria were largely localized in thetained mitochondria. Wild-type cells treated with neuroprotective molecules SS31 (D)
r BrdU incorporation intomitochondria. Representative images for all treatment groups,
o change in BrdU staining in the cell body (D and H), but it did result in reduced BrdU
U staining in the cell body or the neurites. A mildly toxic dose of H2O2 (25 μM) caused an
nd K). A higher dose (100 μM) resulted in the loss of BrdU staining in both the cell body
in an accumulation of BrdU staining in the cell body and a dose-dependent decrease in
wn (H, I, J and K). *pb0.05 compared to the vehicle-treated group. **pb0.005 compared
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BrdU into the cell body and neurites was impaired.
3.5. Cells treated with mitochondrial antioxidants show alterations in
BrdU labeling
We tested whether the mitochondria-targeted antioxidant SS31
(1 nM) altered BrdU labeling of mitochondria in wild-type neurons
(Fig. 4D). Cells treated with SS31 for 48 h and BrdU for 20 h were
stained to evaluate BrdU incorporation. We found that BrdU in the
neurites was reduced from 0.209±0.027 BrdU positive/μm neurite in
untreated cells to 0.149±0.022 BrdU positive/μmneurite (p=0.049).
Labeling within the cell body was unchanged (Fig. 4H, untreated,
32.1±2.9 BrdU positive/cell body; SS31 treated, 33.5±3.5 BrdU
positive/cell body).
Cells were also treated with 10 μM resveratrol, which is thought to
inducemitochondrial biosynthesis. We did not see signiﬁcant changes
in BrdU labeling after resveratrol treatment. The neurite content of
BrdU labeling was slightly reduced to 0.187±0.014 BrdU positive/μm
neurite (p=0.234 compared to untreated) (Fig. 4J). Cell body content
was slightly increased to 36.8±6.1 BrdU positive/cell body (p=0.251
compared to untreated).
4. Discussion
In the present work, we demonstrated that newly synthesized
mtDNA can be labeled using BrdU incorporation in primary murine
hippocampal neurons. We found BrdU labeled mitochondria in the
soma and distal regions of neurons. However, in neurons from AβPP
mice andwild-type primary neurons exposed tomitochondrial toxins,
rotenone and H2O2, mitochondria are concentrated in the soma and
may not be able to transport to distal regions of the neurons. These
ﬁndings led us to conclude that those mitochondrial toxins and Aβ
fragment mitochondria excessively and impair distribution of mito-
chondria to distal regions.
4.1. BrdU labeling and distribution of mitochondria in primary neurons
It is well documented that BrdU labeling has been used to identify
newly synthesized DNA in mammalian cells and post-mitotic cells such
as neurons (reviewed in [38,39,42]). In the present study, we
investigated mtDNA synthesis in neurons from AβPP mice, and wild-
type mice treated with mitochondrial toxins, H2O2 and rotenone, and
protective molecules, such as SS31 and resveratrol after incorporating
BrdU for 4 and 20 h. We identiﬁed newly synthesized mtDNA in all our
experiments for 4 and 20 h incorporation. These resultswere veriﬁed by
co-labeling analysis using immunostaining of mitochondrial-speciﬁc
marker, porin and BrdU. We noticed that 20 h incorporation of BrdU
identiﬁes increased labeling of mitochondria.
The process of mitochondrial biosynthesis is highly interlinked
with mitochondrial ﬁssion, and therefore BrdU labeled mitochondrial
DNA content reﬂects both mitochondrial biosynthesis and ﬁssion.
Mitochondrial DNA replication occurs in existing organelles largely
within the cell soma. After DNA replication, the organelle will undergo
Drp1 mediated ﬁssion to produce two daughter mitochondria. Both of
these daughter mitochondria are expected to carry the BrdU labeled
DNA. Without a ﬁssion event to separate the mitochondria, BrdU
labeling would occur as a single punctum with high intensity. Under
conditions of enhanced Drp1 activation and normal mtDNA synthesis,
the number of BrdU puncta would be increased.
4.2. Impaired mitochondrial biogenesis in primary neurons from AβPP
mice
While measurements of the half-life of mitochondrial proteins
have been controversial [43], it has been estimated that the half-life ofmitochondria in brain tissue is up to 3 or 4 weeks [44]. An extended
lifespan in neurons would not be unexpected, considering the high-
energy requirement for the production and distribution in these
specialized cells. In the current study, we found that mitochondria
with newly synthesized mtDNA comprised about 40% of the total
population after 20 h of BrdU labeling, indicating that newly
synthesized mtDNA rapidly distributed throughout the mitochondrial
population in neurons. This observation implies that while mitochon-
drial constituents are long lived, the rate at which new DNA synthesis
occurs is relatively high. This new DNA is likely, quickly distributed
throughout the mitochondria, through the process of mitochondrial
recycling.
Mitochondrial biogenesis may be a generalized compensatory
response to mild oxidative toxicity. In support of this hypothesis,
increased transcription of mitochondrial-encoded genes was found in
AβPP mice (Tg2576 line) early in disease progression [45]. Further, in
angiotensin II (ROS inducer)-treated mice, the hearts of mice
exhibited an increased upregulation of mitochondrial biogenesis
[46], indicating that the increase in mitochondrial biogenesis may be a
compensatory response to mitochondrial toxicity caused by angio-
tensin II. Recent studies have found that mitochondrial fragmentation
is to be increased in Aβ-treated neurons [7] and to be overexpressed
in mutant, in wild-type APP neurons [9,10], and in neurons treated
with other toxins, indicating that toxins and mutant proteins are
capable of inducing mitochondrial ﬁssion.
In a recent electron microscopy study, we [7] found signiﬁcantly
increased numbers of mitochondria in mouse neuroblastoma (N2a)
cells treated with Aβ25–35 peptide relative to untreated N2a with Aβ,
suggesting that Aβ increased mitochondrial fragmentation. Further,
most of these Aβ-induced mitochondria were structurally damaged,
and the damaged mitochondria were not able to transport to axons
and to distal regions. Those observations are consistent with our
present ﬁndings of BrdU labeled cells that were treated with
mitochondrial toxins which concentrate mostly in the soma. These
observations led us to conclude that structurally damaged mitochon-
dria (induced by mitochondrial toxins and overexpressed mutant
proteins) are not able to transport to terminals.
4.3. Impaired mitochondrial biogenesis and defective mitochondrial
distribution in neurons exposed to toxins
Our data show that under relatively mild oxidative conditions,
BrdU labeling within neurites is reduced with a coincident increase in
the cell body. Many of these BrdU labeled mitochondria in the cell
body are localized to the perinuclear space. Under a greater oxidative
insult, such as 100 μM H2O2, BrdU incorporation into neuronal
mitochondria is drastically reduced in both neurites and cell body,
as the cells are presumably committed to death. The increase in cell
body BrdU puncta may result from one of several mechanisms. First, it
is possible that mild oxidative conditions stimulate increased
mitochondrial biogenesis. Second, it is possible that increased
mitochondrial ﬁssion is initiated without concomitant increase in
DNA replication. Third, an accumulation in the cell bodymay be due to
decreased ability of the organelles to undergo anterograde transport
in neuritic processes. It is also possible that all of these mechanisms
play a role.
4.4. Impact of protective molecules on mitochondrial biogenesis in
primary neurons
Increasing evidence suggests that mitochondrial-targeted antiox-
idants, such as SS31 and MitoQ, protect mitochondria from toxicity
against mutant proteins and other oxidative insults [7,47,48]. The
antioxidant molecules enter the mitochondria at several hundred fold
and scavenge free radicals, prevent the opening of the mitochondrial
permeability transition pore, decrease mitochondrial swelling and
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we found that SS31 and MitoQ reduced Aβ toxicity, exhibited less
mitochondrial damage, and the number of intact mitochondria
increased, suggesting that the SS31 and MitoQ balance ﬁssion and
fusion machinery and enhance neuronal function [7]. Therefore, to
further examine the role of ﬁssion and fusion on N2a cells, we sought
to determine the effect of SS31 on mitochondrial biogenesis. We
treated primary neurons with SS31 and the anti-aging agent
resveratrol, and we studied newly synthesized mtDNA. As described
above, the number of BrdU-labeled mitochondria in the cell body
remained unchanged or increased just slightly, indicating that SS31
serves to promote intact mitochondria. These ﬁndings are consistent
with ﬁndings from an earlier study in which N2a cells treated with
SS31 and MitoQ showed that mitochondrial number is similar to
untreated cells [7]. In the cells treated with resveratrol, the number of
BrdU labeled mitochondria was unchanged in the cell body and in the
neurites, indicating that resveratrol is not involved in fragmenting
mitochondria. To increase neuronal function, it is not critical or
necessary to have an increased number of mitochondria; rather, what
is necessary is that the mitochondria that are present in the neurons
need to be healthy and functionally active. Further research is needed
to develop drugs/agents that promote healthy and functionally active
mitochondria, not just to increase the number of mitochondria per se.
4.5. Mitochondrial biogenesis is mainly in the soma
mtDNA synthesis is known to occur largely in the cell body [30], but
there is evidence that it occurs in neurites aswell [38]. Our data showed
that the majority of BrdU-labeled mitochondria occur within or very
near the cell body, supporting the notion that mitochondrial biogenesis
is largely dependent on factors within the soma. In a healthy, normal
state, newly formed mitochondria are available for anterograde
transport to the distal regions of the neuron, where they will supply
the necessary ATP to satisfy the high-energy demands of synaptic
activity. However, as in this study, in neurons in a diseased state or in
neurons exposed to toxins, mitochondria are excessively fragmented
and produce large numbers of small, defective mitochondria. These
defective mitochondria stay mostly in the soma and do not (or perhaps
are unable to) transport todistal regionsof theneurons, hencedepriving
nerve terminals of ATP. This ATP deprivation may ultimately decrease
synaptic activities and increase synaptic degeneration. This view is
supported by ﬁndings from our lab [15] and others [18,53,54], which
indicate that mitochondrial anterograde transport is impaired in Aβ-
treated cultures. The changes we observed in the BrdU-labeled
mitochondrial distribution, as well as the overall decrease in neuritic
mitochondria, suggest that transport of newly synthesized mitochon-
dria may be impaired in AβPP cells as well.
In summary, BrdU labeling of mtDNA synthesis allowed us to
assess newly synthesized mtDNA in the cell body and in neurites of
neurons. We found that Aβ and mitochondrial toxins enhanced
mitochondrial fragmentation, and these defective mitochondria were
not able to transport to axons, dendrites, and nerve terminals.
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